These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19153119)

  • 1. The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy.
    Vazquez-Martin A; Oliveras-Ferraros C; del Barco S; Martin-Castillo B; Menendez JA
    Ann Oncol; 2009 Mar; 20(3):592-5. PubMed ID: 19153119
    [No Abstract]   [Full Text] [Related]  

  • 2. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
    Ben Sahra I; Le Marchand-Brustel Y; Tanti JF; Bost F
    Mol Cancer Ther; 2010 May; 9(5):1092-9. PubMed ID: 20442309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt.
    Janjetovic K; Vucicevic L; Misirkic M; Vilimanovich U; Tovilovic G; Zogovic N; Nikolic Z; Jovanovic S; Bumbasirevic V; Trajkovic V; Harhaji-Trajkovic L
    Eur J Pharmacol; 2011 Jan; 651(1-3):41-50. PubMed ID: 21114978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Menendez JA
    Cell Cycle; 2009 Jan; 8(1):88-96. PubMed ID: 19106626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPK: a target for drugs and natural products with effects on both diabetes and cancer.
    Hardie DG
    Diabetes; 2013 Jul; 62(7):2164-72. PubMed ID: 23801715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doctors seek to prevent breast cancer recurrence by lowering insulin levels.
    Hede K
    J Natl Cancer Inst; 2008 Apr; 100(8):530-2. PubMed ID: 18398091
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours.
    Cai H; Everett RS; Thakker DR
    Br J Pharmacol; 2019 Aug; 176(15):2724-2735. PubMed ID: 31032880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-diabetic drug metformin: challenges and perspectives for cancer therapy.
    Snima KS; Pillai P; Cherian AM; Nair SV; Lakshmanan VK
    Curr Cancer Drug Targets; 2014; 14(8):727-36. PubMed ID: 25329671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targets of metformin antitumor action.
    Sośnicki S; Kapral M; Węglarz L
    Pharmacol Rep; 2016 Oct; 68(5):918-25. PubMed ID: 27362768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
    Guppy A; Jamal-Hanjani M; Pickering L
    Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metformin, an antidiabetic molecule with anti-cancer properties].
    Beck E; Scheen AJ
    Rev Med Liege; 2013 Sep; 68(9):444-9. PubMed ID: 24180199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin and cancer.
    Rizos CV; Elisaf MS
    Eur J Pharmacol; 2013 Apr; 705(1-3):96-108. PubMed ID: 23499688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?
    Chandel NS; Avizonis D; Reczek CR; Weinberg SE; Menz S; Neuhaus R; Christian S; Haegebarth A; Algire C; Pollak M
    Cell Metab; 2016 Apr; 23(4):569-70. PubMed ID: 27076070
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting AMPK in the treatment of malignancies.
    Vakana E; Altman JK; Platanias LC
    J Cell Biochem; 2012 Feb; 113(2):404-9. PubMed ID: 21928327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
    Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
    Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin as an Anticancer Agent.
    Vancura A; Bu P; Bhagwat M; Zeng J; Vancurova I
    Trends Pharmacol Sci; 2018 Oct; 39(10):867-878. PubMed ID: 30150001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin and pancreatic cancer: a clue requiring investigation.
    Pollak M
    Clin Cancer Res; 2012 May; 18(10):2723-5. PubMed ID: 22465829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.